Kornimate/medical-research-clean huggingface dataset:
dietary treatment of endometriosis-related irritable bowel syndrome

Conditions: Endometriosis; Irritable Bowel Syndrome; Visceral Syndrome; Visceral Hypersensitivity

Summary: many patients with endometriosis experience extra genital and abdominal symptoms as a major part of their problem. this includes gastrointestinal dysfunction with pain, urinary symptoms compatible with interstitial cystitis and gastrointestinal symptoms resembling the irritable bowel syndrome (ibs). such problems may be secondary to changes in autonomous neuronal structure and function elicited by the endometriotic elements, which may cause a "visceral syndrome" with the above mentioned symptoms. the investigators hypothesize that dietary treatment will improve the experience of gastrointestinal symptoms, pain and quality of life in patients with endometriosis-related irritable bowel syndrome. the aim of this first randomized, placebo controlled pilot study investigating patients with both endometriosis and ibs, is to test the application of a low fodmap diet and a placebo diet for endometriosis-related ibs-like symptoms in order to stablish a platform for a randomized controlled study. thus, the primary aim of this pilot study is to investigate the applicability of a placebo diet in patients with endometriosis and to investigate the compliance in both intervention group and control group. in addition, the aim is to investigate whether the participants find the diet manageable and whether they are able to identify the placebo diet.


Eligibility criteria:
inclusion criteria: * signed informed consent * age 18-50 years * fluid spoken and written danish * diagnosed endometriosis (laparoscopy and/or mr-scan) at least one year ago and sufficient treated regarding medicine and surgery. participant will be asked to bring a copy of their medical record from the hospital or from www.sundhed.dk to verify the diagnosis. * diagnosis of irritable bowel syndrome according to the rome iii criteria. both previous diagnosis and undiagnosed patients are included, as long as the study group evaluates that the patient meets the rome iii criteria. * accept to follow a controlled exclusion diet for all meals for four weeks with only few accepted deviations from the diet. exclusion criteria: * premature menopause * organic bowel disease (celiac disease, ibd, bowel endometriosis, malignant disease) * new therapeutic interventions during study period (medical/lifestyle/psychological). already ongoing treatment is accepted. * psychiatric disorder, psychotropic drugs * patients, who the dietician accesses are familiar with low fodmap diet and therefore is able to identify the placebo diet * patients with complicated dietary needs, e.g. severe allergies or intolerances (including lactose and fructose intolerance), athletes, any type of vegetarianism or metabolic diseases * pregnancy or planned pregnancy during the study period

Keywords: endometriosis ibs irritable bowel syndrome low fodmap diet fodmaps visceral syndrome fermentable carbohydrates visceral hypersensitivity cross organ effect
clinical study on the treatment of anorexia and cachexia in advanced gastric and esophageal cancer with nanosized megestrol acetate combined with immunochemotherapy

Conditions: Advanced Gastroesophageal Cancer

Summary: this study is a prospective, randomized, parallel-controlled, multicenter clinical study. the purpose of this study is to evaluate the efficacy and safety of nanocrystalline megestrol acetate combined with the first-line standard immunochemotherapy regimen compared with the first-line standard immunochemotherapy regimen in the treatment of anorexia and cachexia in advanced gastric and esophageal cancer. eligible patients with gastric and esophageal cancer will be randomly assigned in a 1:1 ratio to the nanocrystalline megestrol acetate combination group (referred to as the megestrol acetate group for short) or the first-line standard immunochemotherapy group (referred to as the standard control group for short).


Eligibility criteria:
1. aged between 18 and 75 years old, regardless of gender； 2. the eastern cooperative oncology group (ecog) performance status score is 0-2； 3. the expected survival time is more than 3 months； 4. good organ function
safety and effectiveness study of the precision scs systems adapted for high-rate spinal cord stimulation

Conditions: Chronic Pain; Back Pain

Summary: to evaluate the safety and effectiveness of the precision spinal cord stimulator systems adapted for high-rate spinal cord stimulation as an aid in the management of chronic intractable pain

to evaluate the safety and effectiveness of high rate spinal cord stimulation (hr-scs) therapy as an aid in the management of chronic intractable pain of the trunk using the boston scientific (bsc) precision spinal cord stimulator systems adapted for high-rate spinal cord stimulation

Eligibility criteria:
inclusion criteria: * have been diagnosed with chronic, intractable pain of the trunk (nrs ≥ 5) which has been refractory to conservative therapy for a minimum of 90 days. * be an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician * be 22 years of age or older at the time of enrollment * be willing and capable of giving informed consent * be willing and able to comply with study-related requirements, procedures, and visits exclusion criteria: * have a medical condition or pain in other area(s), not intended to be treated with scs, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the investigator * have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcome, as determined by a psychologist * have previous spinal cord stimulation trial or is already implanted with an active implantable device(s) (e.g. pacemaker, drug pump, implantable pulse generator) * have a current systemic infection, or local infection in close proximity to anticipated surgical field * pregnant or plan to get pregnant during the course of the study or not using adequate contraception. * be participating in another clinical study that may influence the data collected for the study
effect of phytochemicals from theobroma cacao on mental energy

Conditions: Mental Fatigue

Summary: the purpose of this study is to determine which substances in cocoa produces changes in mental energy. this is a double blind study. the primary outcome measures are performance on tasks of sustained attention (serial subtract, continuous performance test and bakan task) at pre and 90, 120 and 160 minutes post intervention, energy and fatigue symptoms (profile of mood state), and ratings of motivation to perform cognitive tasks. the assigned interventions are the following:

only one prior study has examined the acute influence of cocoa on mental energy. the purpose of this research is to replicate the previous observations and extend research in four ways: 1) start to determine which substance in cocoa responsible for the effect by including several comparison groups, 2) focus on individuals with average or below average symptoms of mental energy and who are not high consumers of fruits, vegetables and other products containing high amounts of flavonoids in order to learn whether people with low energy accrue a greater benefit, and 3) include additional measures of mental energy plausibly influenced by cocoa to better understand the health consequences of cocoa.

Eligibility criteria:
inclusion criteria: * women and men ages 18-34 * lower than average feelings of energy (score of \< 13 on profile of mood states vigor scale) exclusion criteria: * pregnant * gi tract disorder * psychoactive medication use * daily consumption of \> 200 mg caffeine * body mass index \> 30 * cigarette smoker * allergy to cocoa, chocolate or caffeine * frequent consumption of cocoa, chocolate-based products or fruits and vegetable containing flavonoids

Keywords: cacao theobromine flavanols caffeine sustained attention vigilance vigor vitality energy fatigue
treatment of uremic pruritus by olive-omega 3 ointment

Conditions: Uremic Pruritus

Summary: background. uremic pruritus is still a common phenomenon in patients with end-stage renal failure. it is regarded as one of the most bothersome symptoms in patients on chronic dialysis. the pathogenesis of uremic itch remains unclear. several theories have been proposed like dryness of the skin, imbalance in divalent ions, peripheral neuropathy and others. many treatment modalities have been tried to reduce uremic pruritus, however , the majority of them produced only temporary improvement. therefore , every new therapeutic option for uremic pruritus is desirable. this study will undertaken to evaluate the efficacy of a cream which included olive oil and omega-3 fatty acids. olive omega-3 is an efficient product that soothes itchiness of cracked and very dry skin. the product is unique and based on patented technology developed by the technion research and development foundation in haifa. olive omega-3 is an ointment composed of all natural ingredients. the main active ingredients are extra virgin olive oil , fish oil and vitamin c. the oils provides the skin with fatty acids that are vital for its proper functioning and help in the skin recovery. sugar cane extract improves the skin's flexibility by removing dead cells and enhancing water retention in the upper layer of the skin. when applied on clean skin , the product is quickly absorbed , producing a sensation of relief within a short time period. treatment can be repeated as often as required with no limitations and its use is not contraindicative of any other medical treatment. patients and methods. about 20 patients on chronic hemodialysis suffering from uremic pruritus will be include in the study. all patients will undergo dermatologic examination. all patients will be score by intensity of itching according to 3-point scale , as follows: 1. - patches of fine , powdery scales 2. - moderate scaling with beginning cracks 3. - intense scaling , moderate cracks the patients all applied olive omega-3 ointment for 50% of body and vaseline ointment for the second one. the treatment will repeated twice daily for two weeks. at the end of 2 weeks application global tolerance will evaluate using the following 3-point scale: 1. very good 2. good 3. poor at the same time global agreement of the patients will evaluate according to the following scale : 1. - very satisfactory 2. - satisfactory 3- poorly satisfactory. statistical analysis will be performed by use of wilcoxon test .


Eligibility criteria:
inclusion criteria: * hemodialysis patients which have treated at least 3 months exclusion criteria: * dermatologic diseases

Keywords: uremia pruritus oliva-omega 3
prevention of pelvic lymphocele by floseal during pelvic lymphadenectomy for gynecologic cancer

Conditions: Gynecologic Cancer

Summary: pelvic lymph node dissection (plnd) is an important step in the surgical staging and treatment of gynecologic malignancies. sometimes, complicated lymphoceles after plnd often delay adjuvant treatment including chemotherapy and radiation therapy, which potentially affects the success of cancer treatment. a number of surgical techniques have developed, but failed to reduce the incidence of pelvic lymphoceles after plnd. the investigators hypothesized that floseal can prevent lymphoceles in patients with gynecologic cancer who has undergone plnd. the investigators designed prospective randomized controlled study as a pilot study. the investigators will randomly apply floseal to one side of pelvis after bilateral plnd, and observe the occurence of pelvic lymphoceles after 6 months later.


Eligibility criteria:
inclusion criteria: * gynecologic cancer patients who need laparotomic bilateral plnd exclusion criteria: * incomplete plnd which can influence the occurrence of lymphocele (surgeon's decision)
phase ii trial with metronomic, capecitabine plus oral vinorelbine for metastatic breast cancer

Conditions: Breast Cancer

Summary: the study hypothesis is that metronomic treatment is more efficient than standard treatment.

purpose: in an open-label randomized phase ii trial, patients with metastatic human epidermal growth factor receptor 2-negative breast cancer with normal organ function sant who performance status \< 3 are randomized to receive either capecitabine (day 1-14) plus vinorelbine oral (day 1 and 8) or capecitabine (day 1-14) plus vinorelbine oral metronomic (3 days a week).

Eligibility criteria:
inclusion criteria: * locally advanced or metastatic human epidermal growth factor receptor2-negative breast cancer * who performance status \< 3 exclusion criteria: * former treatment with capecitabine or vinorelbine * patients who have received more than one line of chemotherapy for metastatic disease * brain metastases * malabsorption syndrome * abnormal organ function * pregnant or lactating women

Keywords: breast cancer metronomic chemotherapy vinorelbine navelbine capecitabine xeloda antineoplastic agents
thermal ablation versus parathyroidectomy for primary hyperparathyroidism

Conditions: Cure Rate; Complication Rate; Efficacy and Safety

Summary: this study is a prospective, multicenter study designed to compare the efficacy and safety of surgical treatment versus ablation therapy (including radiofrequency ablation and microwave ablation) for patients with primary hyperparathyroidism (phpt). the study will assess the impact of both treatment modalities on serum parathyroid hormone (ipth) and calcium levels, clinical symptom improvement, bone mineral density enhancement, reduction in the incidence of urinary system stones, and postoperative complication rates. while surgical treatment has been the standard of care for phpt, offering definitive cure, it carries inherent surgical risks and complications. ablation therapy, as a minimally invasive approach, presents a novel alternative with reduced trauma and fewer complications. the outcomes of this study will inform clinical decision-making and potentially optimize treatment strategies for patients with phpt.


Eligibility criteria:
inclusion criteria: * symptomatic patients with primary hyperparathyroidism, such as those with symptoms in any system including the kidneys, bones, gastrointestinal tract, psychoneurological system, or those with atypical symptoms such as muscle weakness, dysfunction, and sleep disorders. * asymptomatic phpt patients with any of the following conditions: ① serum calcium is higher than the upper limit of the normal value by 1 mg/dl (0.25 mmol/l); ② there is objective evidence of renal involvement, including asymptomatic kidney stones, nephrocalcinosis, hypercalciuria (24 - hour urinary calcium level \> 400 mg/dl) on renal imaging, or impaired renal function (glomerular filtration rate \< 60 ml/min); ③ there is evidence of osteoporosis (bone mineral density decreased by 2.5 standard deviations at any site) and/or radiographic evidence of fragility fractures. ④ age \< 50 years ⑤ the patient cannot accept routine follow - up observation. * imaging examination shows that at least one parathyroid gland is enlarged. exclusion criteria: * diagnosis of secondary or tertiary hpt * severe coagulation disorder * severe cardiopulmonary insufficiency
educational eczema video intervention

Conditions: Eczema

Summary: the objectives of this study are to increase families' understanding of eczema and improve eczema management in the primary care setting. the investigators plan to create an educational video for families providing general information about eczema as well as instructions about good skincare management and common treatments. the investigators will conduct a randomized controlled trial of the plan in the primary care clinic at boston children's hospital. specifically, the investigators aim to (1) decrease eczema severity (2) improve patient and family quality of life (qol) and (3) increase parental knowledge about eczema and eczema management.


Eligibility criteria:
inclusion criteria:eligibility criteria include the following: * accompanying adult speaks english * patient has a history of eczema * patient is between the ages of 1 month and 16 years * accompanying adult is a primary caregiver * child is not in foster care * accompanying adult is 18 years old or older. exclusion criteria: * accompanying adult does not speak english * accompanying adult is not the primary caregiver * accompanying adult is not 18 years old or older * patient is in foster care

Keywords: atopic dermatitis eczema
determinants of the success of flap reconstruction: outcome analysis of 484 surgeries for pressure injury

Conditions: Pressure Injury

Summary: background: pressure injury (pi) mainly occurs in bedridden older adults or those with physical limitations. pi treatment is typically long-term, requiring coordination between health-care workers and the patient's caregiver. here, we aimed to determine the appropriate timing to conduct flap reconstruction in patients with pis and identify factors affecting surgical outcomes. materials and methods: we retrospectively reviewed the data of all patients who received debridement or flap reconstruction surgery for pis in our hospital from january 2016 to december 2021. the extracted data included patient demographics, surgical records, blood test results, vital signs, and flap outcomes. next, these characteristics including the flap outcomes of our patients with pis were analyzed, along with the risk factors for poor wound healing and complications.


Eligibility criteria:
inclusion criteria: all patients who received debridement or flap reconstruction surgery for pressure injury in wan fang hospital from january 2016 to december 2021 exclusion criteria: the patients who did not received debridement or flap reconstruction surgery for pressure injury
quality of life after cytoreductive surgery and intraperitoneal chemotherapy

Conditions: Colorectal Cancer Metastatic

Summary: cytoreductive surgery with intraperitoneal chemotherapy is one of the most important treatments for patients with colorectal cancer and peritoneal metastasis. for the best survival rates, complete removal of all metastatic lesions is the most important part of treatment, and various surgical procedures are required for the complete cytoreduction. therefore, the postoperative morbidity rates are higher than those of localized colon cancer surgeries and patients can experience a prolonged recovery period and deterioration of physical activities over a long period. the aim of this study is to investigate the change of quality of life after cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer.


Eligibility criteria:
inclusion criteria: * colorectal cancer peritoneal metastasis * pseudomyxoma peritonei * ecog (eastern cooperative oncology group) performance status 0-3 * normal bone marrow, kidney, and liver function * patient must sign and date the informed consent exclusion criteria: * palliative surgery * palliative intraperitoneal chemotherapy * psychotic disorder * drug abuser
a study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with bimzelx® (bimekizumab)

Conditions: Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis; Axial Spondyloarthritis; Hidradenitis Suppurativa

Summary: primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.


Eligibility criteria:
inclusion criteria: * study participant must be at least 18 years of age at the time of signing the informed consent. * study participant is being treated with commercial bimekizumab per locally approved prescribing information and in accordance with her treating physician. * study participant is breastfeeding and intends to breastfeed throughout the sampling period. * the decision to treat with bimekizumab and to breastfeed is made independently from and prior to the study participant consenting to participate in the study. * study participant must be on bimekizumab treatment for at least 12 weeks after delivery and since starting/restarting/continuing bimekizumab prior to sampling (prior to start of the sampling period). * a female study participant is eligible to participate if she is not pregnant and does not plan to become pregnant during the study. exclusion criteria: * study participant has any medical, obstetrical, or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study. * the infant has any abnormality noted on physical examination or medical history that, in the opinion of the investigator, may jeopardize or compromise study participation. * study participant has a history of chronic alcohol or drug abuse within the previous last year. * study participant has history of breast implants, breast augmentation, or breast reduction surgery. * study participant plans a surgical intervention during the screening period and sampling period or anticipates having surgery while participating in the sampling period (does not apply to tubal ligation). * study participant or her infant has participated in another study of an investigational medicinal product (imp) (and/or an investigational device) within the previous 6 months or is currently participating in another study of an imp (and/or an investigational device), unless the study is ucb ps0036 or a bimekizumab registry study. * study participant or her infant has previously participated (ie, entered the sampling period) in this study.

Keywords: bimekizumab breastfeeding mothers bimzelx® pso hs axspa psa